Valganciclovir

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

IndicationThis section has been translated automatically.

Cytomegalovirus retinitis in patients with HIV infection (AIDS), prophylaxis of CMV disease in CMV negative patients who have received an organ transplant from a CMV positive donor.

Limited indicationThis section has been translated automatically.

Renal insufficiency, dialysis patients, leukopenia, neutrocytopenia < 500/µl, thrombocytopenia < 25,000/µl, Hb < 8 g/dl.

Pregnancy/nursing periodThis section has been translated automatically.

Contraindicated.

Dosage and method of useThis section has been translated automatically.

Initial: 2 times/day 900 mg p.o. for 21 days. Maintenance therapy: 900 mg once/day. Maintenance therapy and prophylaxis for organ transplant patients: 900 mg once a day. If the retinitis worsens, the dose may be increased as in initial therapy (risk of drug resistance exists!).

Undesirable effectsThis section has been translated automatically.

ContraindicationThis section has been translated automatically.

Use in patients < 18 years of age. Hypersensitivity to Aciclovir and Valaciclovir i.A.

PreparationsThis section has been translated automatically.

Valcyte

Note(s)This section has been translated automatically.

Remember! Damage to the genetic material is potentially possible. Therefore, men under treatment should not conceive a child 6 months after therapy. Women should use effective contraception during treatment!

Authors

Last updated on: 29.10.2020